Understand the source comparison
SS-LUP-332 Work for Novel Mitochondrial Research: Full Comparison
SS-LUP-332 Direct PGC-1α promoter binding Moderate (oral ~30%, IP ~70%) No. Bypasses AMPK entirely 10–20mg/kg twice daily 40–65% increase in mtDNA copy number over 14 days Best choice for insulin-resistant or AMPK-impaired models where other modulators fail Re
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-LUP-332
- Direct PGC-1α promoter binding
- Moderate (oral ~30%, IP ~70%)
- No. Bypasses AMPK entirely
- 10–20mg/kg twice daily
- 40–65% increase in mtDNA copy number over 14 days
- Best choice for insulin-resistant or AMPK-impaired models where other modulators fail
- Resveratrol
- AMPK activation → PGC-1α upregulation
- Poor (oral <5% due to first-pass metabolism)
- Yes. Requires functional AMPK signaling
- 50–150mg/kg once daily
- 15–25% increase in mtDNA copy number over 21 days
- Effective in healthy models but inconsistent results in metabolic disease states
- Metformin
- AMPK activation via Complex I inhibition
- High (oral ~50–60%)
- Yes. Primary mechanism is AMPK-dependent
- 200–500mg/kg once daily
- 20–35% increase in muscle mitochondrial content over 28 days
- Proven in human diabetes trials but requires chronic dosing; acute effects minimal
- NAD+ Precursors (NMN/NR)
- Increases NAD+ → activates sirtuins → PGC-1α deacetylation
- Moderate (oral ~30–40% for NMN)
- Partially. Sirtuins modulate AMPK activity
- 300–500mg/kg once daily
- 25–40% increase in mitochondrial markers over 21 days
- Strong human translation data but expensive; best for aging research
- Bezafibrate
- PPARα/δ agonist → PGC-1α upregulation
- High (oral ~80%)
- No. Acts through PPAR nuclear receptors
- 100–200mg/kg once daily
- 30–50% increase in oxidative capacity in muscle
- Clinical-grade compound with human safety data but limited CNS penetration